Julie Andrews Sells 4,655 Shares of Orthofix Medical Inc. (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now owns 28,312 shares of the company’s stock, valued at approximately $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Orthofix Medical Stock Up 0.1 %

OFIX stock opened at $18.38 on Thursday. The firm has a 50-day moving average price of $18.07 and a 200-day moving average price of $16.93. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $702.37 million, a P/E ratio of -5.87 and a beta of 1.10.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.57). The company had revenue of $196.61 million during the quarter, compared to the consensus estimate of $196.60 million. Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. During the same period in the previous year, the company earned ($0.77) EPS. As a group, equities research analysts anticipate that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Orthofix Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in shares of Orthofix Medical by 15.7% during the second quarter. American Century Companies Inc. now owns 54,964 shares of the medical device company’s stock worth $729,000 after purchasing an additional 7,475 shares during the last quarter. XTX Topco Ltd bought a new stake in Orthofix Medical during the 2nd quarter worth approximately $175,000. Sei Investments Co. increased its position in Orthofix Medical by 24.6% in the 2nd quarter. Sei Investments Co. now owns 46,195 shares of the medical device company’s stock valued at $613,000 after acquiring an additional 9,114 shares during the period. Gabelli Funds LLC raised its stake in shares of Orthofix Medical by 7.9% during the second quarter. Gabelli Funds LLC now owns 157,500 shares of the medical device company’s stock valued at $2,088,000 after acquiring an additional 11,500 shares during the last quarter. Finally, AREX Capital Management LP lifted its holdings in shares of Orthofix Medical by 5.7% during the second quarter. AREX Capital Management LP now owns 232,500 shares of the medical device company’s stock worth $3,083,000 after purchasing an additional 12,500 shares during the period. Institutional investors own 89.76% of the company’s stock.

Wall Street Analyst Weigh In

OFIX has been the subject of several analyst reports. Canaccord Genuity Group began coverage on Orthofix Medical in a report on Wednesday. They issued a “buy” rating and a $24.00 price objective for the company. Roth Mkm reaffirmed a “buy” rating and set a $22.00 price objective (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Finally, Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and raised their target price for the company from $18.00 to $24.00 in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.